Conferences yesterday: folks on their phone doing emails or social Conferences today: folks on their phones checking chat AIs to figure out what the speaker is going on about 🐮
@genomicscow.bsky.social
Original and probably disagreeable perspectives on genomics. Not sure when I'm joking and when I'm being serious. Opinions my own, not the herd’s.
The unspoken beneficiaries of Chat GPT are the newly brought-in CEOs and other senior managers to a company where they can’t be seen to ask the dumb questions on the technology or biology 🐮
AGBT and ABRF are over… How many of you remember there’s a 10x announcement coming up, on Saturday as well!
NovaSeq X 1.4 software upgrades customer priority lists are the new way Illumina can treat its premium customers now that they are trying to be more disciplined with discounting 🫠
18 months is the new 18 weeks That’s what you can tell your boss now if you do genomics the agbt26 way
Illumina alumni have always been hot-to-hire in the market, but right now they all want to hire Roche (SBX) alumni
Lots of new genomics product announcements! 🚨 Sales/marketing promoting on LinkedIn these products they sell. Ho hum. Recruiters promoting on LinkedIn these products from companies they want to recruit for. Cringe?
Like in politics, the middle powers of genomics might need to band together a bit more Middle power companies are those could get bought by the super powers (Illumina, Thermo, Danaher, etc) If they don’t meet in Davos they should at least meet in Orlando
Instrument-free options for expanding the menu are what’s needed for vendors to survive this environment. It won’t score the revenue beats but it’ll reduce the lumpiness
GenomeWeb@genomeweb.bsky.social · 8mo agoSequencing Firms Stay on Multiomics Path in 2025 Amidst Tough Funding Environment, Global Tensions
AGBT is elitist, over-priced, demands that a written justification for my attendance, in a red state… Woohoo I got accepted!
What took Xenium so long to get protein panels out? These were touted several years ago - Resources taken from Xenium? - Resources in Xenium but needed for other features or bugs to fix? - Chemistry was poorly optimized for dev teams to finalized? But one answer can’t be true: lack of demand.
Just saw that Somalogic nabbed a big win 👏 1. Big non European cohort doing proteomics 👍 2. Competition where SomaScan won 🥇 3. But now Illumina buying Somalogic to run on NGS🦈 4. But why generate this data on a microarray platform w limited future? 🤷♀️ investors.standardbio.com/news-release...
Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study | Standard BioTools Inc.
The Investor Relations website contains information about Standard BioTools Inc.'s business for stockholders, potential investors, and financial analysts.
investors.standardbio.com
Company posting message about how important their products are …and backing this up with a picture of their Chief-anything-Officer with a quote about how much we should believe this #imsold! 🐮
Now waiting for some GWAS studies followed to find cool genes, followed by analyses on how coolness is confounded by mating behavior 😎 www.nytimes.com/2025/06/30/w...
What Makes Someone Cool? A New Study Offers Clues.
nytimes.com
Such timing. Not the LinkedIn part though, that’s still boring
@genomicscow.bsky.social · last yr.Imagine if people were honest on LinkedIn: Instead of congratulating someone on their new role, “This person burned their bridges” Till then, LinkedIn is just one big self-advertising platform 🐮
Call me heartless if you want, but I’m a bit jaded with this pitch: “Someone I knew had a disease, so I started a company…”
Imagine if people were honest on LinkedIn: Instead of congratulating someone on their new role, “This person burned their bridges” Till then, LinkedIn is just one big self-advertising platform 🐮
Milan in May ☀️ or Boston in October? #eshg25 (Actually Boston is simply beautiful in October) 🍁
You can’t eat microchips. Social media can’t heal the sick. B2B SaaS will never love you The final measure of any technology is the value it creates, directly or indirectly, for living things. In this sense, biology is everyone’s mission
Excited and bearish on proteomics risk scores. I hear how they compare favorably to polygenic risk scores But, polygenic risk scores already perform far better than incumbents Performance isn’t the issue To be clear, proteins have many advantages (dynamic, possible with existing dx infrastructure
A relief, followed with regret on wasting energy on emergency meetings for many, I’ll bet Meanwhile illumina isn’t likely to do well in China for a while yet, not just for instruments but probably also consumables
GenomeWeb@genomeweb.bsky.social · last yr.US, China Temporarily Slash Tariffs After Life Sciences Firms Prepared for Impact
Last I read of Vinay Prasad he was generally against large genomics panels for cancer testing - though with reasonable rebuttals Wow his career really took a turn (and off!) from those days!
Fearless, maybe also safe prediction: 2025 is the rise of the fractional CXOs in genomics
Companies have been letting go a lot of staff recently But the firing of Kári Stefánsson from decode in Iceland really sticks out Sounds like Amgen couldn’t be too endless with the popgen programs
“Are you still interested in genomics?” Illumina just sent this to me, giving uninterested ppl a chance to unsubscribe Appreciate the politeness but it’s timing reinforces meekness
Assemble a polygenic risk score for a trait and get an AUC of 0.75 Add some dynamic ‘ome like RNA, methylation or protein and get that number to 0.8+ This hypothetical is a significant improvement but who’s gonna afford 2+ omics to validate your combinatorial signature?